



Platform Technologies to Accelerate Novel Vaccine Development and Manufacturing

Abstract

The vaccine industry has undergone a revolution in technology resulting in a variety of novel therapeutic platforms that accelerate development and significantly reduce the duration for process optimization and scale-up. However, challenges in maintaining efficacy and improving process robustness remain. In this presentation, we present a comparison of these novel technologies, discuss key considerations for manufacturing and share selected case studies for platforms such as virus-like-particles, viral vectors, plasmid DNA, and mRNA platforms.

We will cover these topics:

- Benefits of platform technologies in vaccine development
- Key considerations when deciding between platforms
- Vaccine pipeline analysis and selected case studies

[Click & Register](#)

Details

Date

August 3, 2021, Tuesday

Time

3:00 p.m. Japan

Merck Speaker



Josephine Cheng

Senior Consultant, Core Modalities Asia Pacific, Bioprocessing Strategy



David Loong, Ph.D

Senior Consultant, Novel Modalities Asia Pacific, Bioprocessing Strategy

